Market Research Report
Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026
|Published by||Coherent Market Insights||Product code||785767|
|Published||Content info||167 Pages
Delivery time: 2-3 business days
|Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026|
|Published: July 16, 2018||Content info: 167 Pages||
Increasing prevalence of pompe disease is expected to create lucrative opportunities for pharmaceutical manufacturers to develop and commercialize novel treatments for the disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated incidence of Pompe disease in Holland is 1 in 40,000, in Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and in Caucasian is 1 in 100,000 population. Initiatives from government organizations for drug research and development is supporting growth of the metabolism drugs market.
For instance, in 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and researchers identified a new molecule that shows promising approach for treatment of the rare gaucher disease. Moreover, in 2014, European Gaucher Alliance launched Gaucher Awareness Day to spread awareness about this rare disease among the population in Europe.
Robust pipeline with various therapies such as enzyme replacement therapy, gene therapy, and small molecule drugs is expected to boost the metabolism drugs market over the forecast period. Increased understanding of diseases and rising number of diagnosed patients are expected to increase the number of patients undergoing treatment.
High prevalence of metabolic diseases is expected to support the growth of the metabolism drugs market. For instance, according to the National Institute of Health (NIH) 2018 report, frequency of hunter syndrome is 1 in 100,000 to 1 in 160,000 in males. Enzyme replacement therapy is expected to show significant growth in the metabolism drugs market over the forecast period.
This report provides in-depth analysis of metabolism drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new application launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global metabolism drugs market based on the following parameters – company overview, financial performance, application portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future application launches, technology up-gradation, market expansion, and marketing tactics
The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, application manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the metabolism drugs market